Exscientia Ai Ltd., A Wholly Owned Subsidiary Of Recursion Pharmaceuticals, Inc.

This early-phase study tests an experimental oral drug, EXS73565, in about 50 adults with certain B-cell blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard therapy. The main goals are to check the drug's safety and find the right dose. Researche…

This study tests a new drug called GTAEXS617 in 230 adults with advanced solid tumors, including lung, breast, ovarian, pancreatic, and head and neck cancers. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must ha…

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…